Literature DB >> 19092276

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.

Satoshi Kitai1, Masatoshi Kudo, Yasunori Minami, Seiji Haji, Yukio Osaki, Hiroko Oka, Toshihito Seki, Hiroshi Kasugai, Yo Sasaki, Takashi Matsunaga.   

Abstract

OBJECTIVES: The conventional Japan Integrated Staging (c-JIS) score has been reported to effectively stratify patients with hepatocellular carcinoma (HCC). Recently, two new staging systems, the biomarker-combined JIS (bm-JIS) score and the BALAD score, have been proposed. Both staging systems include three tumor markers: alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP and des-gamma-carboxy prothrombin specific for HCC. The aim of this study is to evaluate the performance of these three staging systems.
METHODS: A total of 1,173 HCC patients were included in this study. The stratification ability and prognostic predictive power were compared between these three staging systems.
RESULTS: These three staging systems effectively predicted the patient survival. When accounting for the best prognostic subgroup of each staging systems (i.e. score of 0), there were significant differences between the bm-JIS score and the BALAD score and, likewise, between the c-JIS score and the BALAD score. The likelihood ratio chi(2) test showed the highest value and the Akaike information criterion value was lowest in the bm-JIS score.
CONCLUSIONS: The bm-JIS score showed good stratification ability and was thus demonstrated to be a better predictor of the prognosis than the c-JIS score and the BALAD score, especially for the patients with a good prognosis. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092276     DOI: 10.1159/000173428

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  17 in total

1.  Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats.

Authors:  Wei-hui Liu; Li-na Ren; Xing Wang; Tao Wang; Ning Zhang; Yuan Gao; Hao Luo; Nalu Navarro-Alvarez; Li-jun Tang
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-28       Impact factor: 4.553

2.  Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines.

Authors:  Brian I Carr; Ziqiu Wang; Meifung Wang; Gang Wei
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

Review 3.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

4.  Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma.

Authors:  Long-Hai Feng; Hui Dong; Wan-Yee Lau; Hua Yu; Yu-Yao Zhu; Yun Zhao; Yu-Xi Lin; Jia Chen; Meng-Chao Wu; Wen-Ming Cong
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-14       Impact factor: 4.553

Review 5.  Staging of hepatocellular carcinoma.

Authors:  Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

Review 6.  Treatment algorithms for managing hepatocellular carcinoma.

Authors:  Vivek A Saraswat; Gaurav Pandey; Sachin Shetty
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

Review 7.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 8.  The status of transarterial chemoembolization treatment in the era of precision oncology.

Authors:  Valerie Fako; Xin Wei Wang
Journal:  Hepat Oncol       Date:  2017-09-26

9.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

Review 10.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.